Picture of Taisho Pharmaceutical Holdings Co logo

4581 Taisho Pharmaceutical Holdings Co Income Statement

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Taisho Pharmaceutical Holdings Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

2019
March 31st
R2020
March 31st
2021
March 31st
2022
March 31st
2023
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:YuhoYuhoYuhoYuhoYuho
Standards:
JAS
JAS
JAS
JAS
JAS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue261,551288,527281,980268,203301,381
Cost of Revenue
Gross Profit170,345180,141175,930163,832177,850
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses249,608261,888264,419258,412279,930
Operating Profit11,94326,63917,5619,79121,451
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes64,48429,77522,97621,39829,498
Provision for Income Taxes
Net Income After Taxes49,82621,53015,19414,95021,302
Minority Interest
Net Income Before Extraordinary Items
Net Income48,59520,17413,31613,12218,997
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income48,59220,17013,31513,12218,997
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS395271283265340
Dividends per Share
Special Dividends per Share